Zumutor Biologics, an Immuno-Oncology company developing novel mABs to drive transformational changes in the treatment of cancer raises 4Mil$ in series A2 funding taking its total raise to 20Mil$. The round includes funding by new investor Bharat Innovation Fund (BIF) with participation from its existing investor, Accel Partners. Zumutor’s growth strategy is focused on Natural Killer (NK) cell activating targets. The company has developed a compelling pipeline of immuno-oncotherapeutics molecules leveraging its antibody discovery platform, INABLR®

Kavitha Iyer Rodrigues, Founder-CEO said: “Our first-in-class lead molecule, ZM 008 has made industry validated progress and is poised for IND filing with Phase 1a/1b clinical trials likely to commence end 2020. Series A 2 funding will enable pivotal milestones in development stages”

Ashwin Raguraman, Founding Partner, Bharat Innovation Fund said: “We are excited to back a world class scientific team, a second time entrepreneur and a company developing immuno-therapeutic products using their proprietary platforms. The strong pipeline that Zumutor has developed combined with a relatively differentiated NK cell approach could lead to breakthrough treatments for multiple cancers”

Barath Shankar Subramanian, Partner at Accel said: “Accel is excited to continue to partner with and support Zumutor in its quest to bring in transformational changes to the way cancer is treated”